Pfizer Corporation

Qingyi Yang

David Andrew Griffith

Matthew Forrest Sammons

Christopher Ryan Butler

Patrick Robert Verhoest

Dafydd Rhys Owen

Jamison Bryce Tuttle

Martin Youngjin Pettersson

Matthew Richard Reese

Michael Aaron Brodney

Lei Zhang

Christopher John Helal

Erik Alphie LaChapelle

Xiaojing Yang

Laura Ann McAllister

Aaron Smith

Michelle Renee Garnsey

Jana Polivkova

Natasha Mariam Kablaoui

Kevin Alexander Ogilvie

Liuqing Wei

Robert Steven Kania

Cynthia Louise Palmer

Kimberly O Cameron

Samit Kumar Bhattacharya

Sajiv Krishnan Nair

Liying Zhang

Kevin Daniel Freeman-Cook

Mehran Jalaie

Eugene Yuanjin Rui

Ping Chen

John M Curto

Brian Kenneth Raymer

Daniel Wei-Shung Kung

Douglas Carl Behenna

Yajing Lian

Damien Webb

Aaron Christopher Smith

The present invention provides, in part, compounds of Formula I: or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: X, X, R, R, m and n are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, Parkinson's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.

Piperazine azaspiro derivatives

Described herein are methods of treating MC4R-related conditions, diseases, or disorders by administering compounds of Formula I:

Methods for antagonizing a melanocortin 4 receptor

Described herein are compounds of Formula I: and their pharmaceutically acceptable salts, wherein R, R, R, X, Y, Y, Y, Yand Yare defined herein; their use as MC4R antagonists; pharmaceutical compositions containing such compounds and salts; the use of such compounds and salts to treat, for example, cachexia, anorexia, or anorexia nervosa; and intermediates and processes for preparing such compounds and salts.

Melanocortin 4 receptor antagonists and uses thereof

The invention relates to compounds of Formula I&#x2033; wherein R, R, R, R, p, q and q' are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.

Nitrile-containing antiviral compounds

The present invention provides, in part, compounds of Formula I: or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: X, X, R, R, m and n are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, Parkinson's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder. 

This invention relates to compounds of general Formula I in which A, R, R, Rand Rare as defined herein, and the pharmaceutically acceptable salts thereof; to pharmaceutical compositions comprising such compounds and salts; to methods of using such compounds, salts and compositions for treating pulmonary hypertension and related diseases, like pulmonary arterial hypertension; to methods of using such compounds, salts and compositions for treating abnormal cell growth, such as cancer; and to processes to make such compounds, salts and compositions.

Anti-proliferative agents for treating PAH

Growing community of inventors

Lexington, MA, United States of America

Qingyi Yang